SURVEYOR-II, Part 3: Efficacy and Safety of ABT-493/ABT-530 in Patients with Hepatitis C Virus Genotype 3 Infection with Prior Treatment Experience and/or Cirrhosis

导出原文传递

翻译打印收藏纠错

作者： Wyles, David L. ^[1] ; Poordad, Fred ^[2] ; Wang, Stanley ^[3] ; Alric, Laurent ^[4] ; Felizarta, Franco ^[5] ; Kwo, Paul Y. ^[6] ; Maliakkal, Benedict ^[7] ; Agarwal, Kosh ^[8] ; Hassanein, Tarek I. ^[9] ; Weilert, Frank ; Lee, Samuel S. ; Liu, Ran ; Lin, Chih-Wei ; Ng, Teresa ; Mensa, Federico

作者单位： Univ Calgary, Calgary, AB, Canada ^[1] AbbVie Inc, N Chicago, IL USA ^[2] Univ Calif San Diego, La Jolla, CA 92093 USA ^[3] Southern Calif GI Ctr, Coronado, CA USA ^[4] Univ Toulouse 3, IRD, Dept Internal Med & Digest Dis, Toulouse, France ^[5] Indiana Univ Sch Med, Indianapolis, IN 46202 USA ^[6] Kings Coll Hosp London, Inst Liver Studies, London, England ^[7] Tawa St Specialist Clin, Hamilton, New Zealand ^[8] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA ^[9]

发布时间 2020-08-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Hepatology

2016年64卷S1期

62A-63A页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

SURVEYOR-II, Part 3: Efficacy and Safety of ABT-493/ABT-530 in Patients with Hepatitis C Virus Genotype 3 Infection with Prior Treatment Experience and/or Cirrhosis

Hepatology

相似文献

Hepatology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

SURVEYOR-II, Part 3: Efficacy and Safety of ABT-493/ABT-530 in Patients with Hepatitis C Virus Genotype 3 Infection with Prior Treatment Experience and/or Cirrhosis

Hepatology

相似文献

Hepatology

相关期刊

检索历史清除